News

MORAb-004 is a humanized monoclonal antibody to endosialin/tumor endothelial marker-1 (TEM-1), which is a protein that is expressed in many human malignancies, and which plays a role in

Omnia offers translational medicine services in the areas of process development, assay development, GMP manufacture and fill-finish for preclinical and clinical programs for therapeutics that do not have

ASG-22ME is an ADC composed of a fully human antibody directed to Nectin-4, an antigen expressed in multiple cancers including bladder, breast, lung and pancreatic cancers. ASG-5ME currently

Silenor is a low-dose (3 mg and 6 mg) oral tablet formulation of doxepin, indicated to treat insomnia characterized by difficulties with sleep maintenance. As per the terms

So far, the company recruited around 500 patients in the trial, whose primary endpoint is overall survival. Merck Serono Oncology Global Clinical Development Unit senior vice president Oliver

Galapagos expects to recruit around 36 subjects in the trial to investigate the safety, efficacy, tolerability and the pharmacokinetics of GLPG0634 in treating RA. The primary efficacy endpoint

As per the agreement, Hovione and PSI will bring their spray-drying based sloid solution technologies to maximize the bioavailability of BCS Class II active pharmaceutical ingredients. Development will

In a Phase IIb open-label trial evaluating infants at 2, 4, 6 months or at 2, 3, 4 months with or without routine vaccines, Bexsero demonstrated that the

Previously, DMC asked Merck to terminate patient recruitment as the study failed to meet the formal futility criteria. The decision was based on the data which showed overall